5 months ago
When Donald Trump said astir supplier prices connected 19 December, he struck a acquainted note. Americans, he said, were paying acold excessively overmuch for medicines – and it was everyone else’s fault.
There would beryllium nary talk of reining successful backstage insurers aliases pharmaceutical profits. Instead, Trump blamed overseas governments for getting a amended deal. Countries for illustration France, Germany and Japan, he argued, were piggybacking connected nan United States by keeping their supplier prices low.
Later that day, astatine a rally successful North Carolina, he performed an imaginary showdown pinch Emmanuel Macron. Trump claimed he had told nan French president that France would person to double aliases triple its supplier prices – and that France would yet springiness in. Thanks to this reliable approach, Trump promised to trim US supplier prices “by 700%”, a fig truthful nonsensical it hardly merits scrutiny.
Trump is correct astir 1 thing: nan US strategy is simply a nationalist wellness failure. Drug prices are eye-wateringly high. Millions of Americans struggle to spend basal medicines specified arsenic insulin. Private insurers adhd costs without improving access. The consequence is simply a state that spends much connected healthcare than anyone else, yet has little life expectancy than galore poorer nations.
But Trump’s mentation is wrong. Americans are not paying precocious prices truthful that European, Canadian, South Korean and Japanese citizens tin bask inexpensive medicines. They are paying precocious prices because pharmaceutical companies complaint what they tin get distant with.
Other countries’ patients and their governments do salary little than Americans, but they hardly get medicines for free. Prices for caller narcotics are precocious and rising everywhere. The existent winners are nan shareholders of multinational pharmaceutical companies who person enjoyed bonzer profits, dividends and stock buybacks complete nan past 2 decades – more than $1,500bn betwixt 2000 and 2018. A mostly of them are US-owned. In 2024, US corporations made 49% of nan apical 20 large pharma revenue.
This matters because Trump’s outburst points to thing bigger than run rhetoric. The United States is now turning against a world pharmaceutical strategy it helped to create.
That strategy took style successful nan 1990s, erstwhile rich | countries pushed reliable intelligence spot rules done world waste and acquisition agreements, particularly nan infamous 1994 Trips agreement. Patent rules were strengthened and harmonized worldwide, pinch devastating effects connected galore patients successful countries limited connected generic manufacturing. The caller patent rules overwhelmingly benefited ample pharmaceutical firms based successful nan US, Europe and Japan.
In return, done parallel waste and acquisition agreements, poorer countries were offered entree to rich | markets for their manufactured equipment and were drawn into world proviso chains. The strategy delivered immense profits for pharmaceutical investors – but besides restricted entree to medicines and pushed prices ever higher.
Today, that exemplary is nether strain. Pharmaceutical companies are spending a smaller stock of their revenues connected research, for innovations that are often judged little innovative by experts, while paying much retired to investors. In 2024, nan US pharma elephantine Pfizer spent conscionable 18% of its gross connected soul investigation and improvement – while 27% went to shareholders done dividends and indebtedness repayment. Innovation has slowed. Breakthroughs that toggle shape nationalist wellness are rarer, while ultra-expensive treatments for mini groups of patients are becoming nan norm.
At nan aforesaid time, countries extracurricular nan aged strategy are catching up. China, for example, has built a ample state-backed pharmaceutical manufacture and now produces vaccines and medicines without relying connected occidental patents. Between 2021 and 2022, Chinese corporations unsocial were capable to nutrient 3.4bn Covid-19 vaccine doses, 28% of each doses produced astatine nan time. Even countries specified arsenic Cuba were speedy to create their ain vaccines done a state-controlled biotech ecosystem.
From Washington’s constituent of view, nan problem is that profits whitethorn person peaked. When US industries look that benignant of pressure, they thin to look for personification other to pay. Trump’s reply is to target friends alternatively than companies.
Instead of challenging pharmaceutical powerfulness astatine home, he wants to unit European and Asian friends to salary much for US drugs, while pushing down prices for US citizens. It is simply a acquainted strategy: usage economical unit connected partners who dangle connected US subject protection and person constricted room to resist.
This could time off governments successful Europe and Japan successful an awkward position. Their home pharmaceutical firms person agelong based on for higher home prices, person to US levels. Private insurers would astir apt not object. But voters would – arsenic nationalist healthcare systems would quickly beryllium incapable to grip moreover much elevated value levels.
Trump presents his scheme arsenic opinionated up for American patients. In reality, it protects nan aforesaid firm interests that made medicines unaffordable successful nan first spot – while exporting nan harm to others.
-
Susi Geiger and Théo Bourgeron are nan authors of Peak Pharma: Toward a New Political Economy of Health (Oxford University Press)
